Tvardi Therapeutics, Inc.

TVRD Healthcare Biotechnology

In the quarter to June 2026, revenue grew 20.3%, EPS fell 235.3% and free cash flow fell 57.3%, each against the same quarter a year earlier.

1.01 0.06 −5.61%
Market cap
$14.3M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
3/9
Altman Z
−5.15
Beneish M
−3.66
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
3.48 2.86 2.25 1.87
Net Debt/EBITDA
6.17 3.97 3.56 2.39
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.45) (0.77) (0.62) (0.98)
Book value per Share
2.97 2.82 1.55 0.89
Free Cash Flow
(4.26) (5.68) (5.86) (9.23)
Other line items

Show all line items

Columns are period end dates